Skip to content
OpenHORIZON-HLTH-2027-02-TOOL-01-two-stageHaDEAOne-off

Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

AI for predictive biomarkers in chronic non-communicable diseases.

Horizon Europe research action (RIA, two-stage) to develop predictive biomarkers of disease progression and treatment response using AI methods for chronic non-communicable diseases.

Next deadline
91
days
17 February 2027
HORIZON-HLTH-2027-02-TOOL-01-two-stage stage 1
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases?

Who
A consortium of at least three independent organisations from three different countries, at least one of which is from an EU Member State and the others from Member States or Associated Countries; companies of any size, research organisations, public authorities, foundations and associations may participate, and organisations from the United States may also receive funding. Entities established in China and high-risk suppliers of mobile network equipment are excluded.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition); Destination; Specific conditions, Eligibility conditions
What for
A research and innovation action that uses existing AI methods to develop and clinically validate predictive biomarkers for the progression of and treatment response in chronic non-communicable diseases (excluding cancer). The aim is to enable personalised treatment of chronic diseases.
Expected Outcome; Scope
What you get
A grant covering 100% of eligible costs; the Commission considers an EU contribution of €6-8 million per project appropriate. The indicative budget for the topic is €44.2 million, expected to fund 6 projects.
Specific conditions (Expected EU contribution per project, Indicative budget); General Annex G, Funding rates
What you need to do
From 29 October 2026, first submit a short proposal via the Funding & Tenders Portal by 17 February 2027 at the latest; if invited, submit the full proposal with Part A and Part B by 16 September 2027 (17:00 Brussels time) at the latest. Independent experts evaluate and rank the proposals; results follow around 3 months after the first and around 5 months after the second deadline.
Budget overview; Application and evaluation forms; General Annex F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

Enable personalised treatment of chronic diseases.

01
New predictive biomarkers
Clinical researchers and developers have access to new predictive biomarkers to assess disease progression and treatment response in chronic non-communicable diseases more accurately.
02
Validated biomarkers in healthcare
Clinicians and healthcare professionals use clinically validated predictive biomarkers for more effective clinical research and personalised medicine with better health outcomes.
03
Trustworthy AI tools
Stakeholders have access to trustworthy AI tools for developing multimodal predictive biomarkers that are more accurate and of greater clinical value than current practice.
04
Better health outcomes
Citizens benefit from better health outcomes thanks to improved clinical guidelines, biomarker-driven clinical research and personalised care.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

The traditional ‘one biomarker’ paradigm is insufficient for addressing the unmet clinical needs of chronic, progressive and multifactorial diseases, due to the complexity of the clinical phenotypes characterised by broad inter-and intra-patient heterogeneity. The established biomarkers have limitations in their use as prognostic and predictive indicators, for the assessment of the disease progression and the choices of the optimal therapeutic interventions tailored to the patients’ characteristics.

Read more

The proposals should allocate a sufficient budget for networking and joint activities, without the prerequisite to detail such activities at the proposal stage.

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions … – the Overseas Countries and Territories (OCTs) linked to the Member States … – countries associated to Horizon Europe … – the following low- and middle-income countries
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
04
Legal entities established in China are not eligible to participate in both Research and Innovation Actions (RIAs) and Innovation Actions (IAs) falling under this destination.
05
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
06
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
07
Entities that are assessed as high-risk suppliers of mobile network communication equipment (and any entities they own or control) are not eligible to participate as beneficiaries, affiliated entities and associated partners.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Onderzoek, ontwikkeling en innovatieDigitalisering, ICT en dataGezondheid, zorg en welzijn
Project phase
ResearchDevelopment
Funding

What do you get?

100% of your eligible project costs.

Note on the maximum
No binding maximum; the Commission considers an EU contribution of €6 million to €8 million per project appropriate.
€44.2m · Indicative topic budget, expected to fund 6 projects.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared under two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

17
FEB
HORIZON-HLTH-2027-02-TOOL-01-two-stage stage 1 closes 17 February 2027
Open since 29 October 2026
Budget overviewActive
Cycle: First-stage results around 3 months after the first-stage deadline and second-stage results around 5 months after the second-stage deadline; grant agreement signature around 8 months after the second-stage deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
HORIZON-HLTH-2027-02-TOOL-01-two-stage stage 2 · closes 16 September 2027Budget overview
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative details of the participants and summary budget (completed online)
  • First stage: Part B of the short proposal, technical description (PDF, maximum 10 pages)
  • Second stage, on invitation: Part B of the full proposal, technical description (PDF, maximum 40 pages)
  • Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Apply via the Funding & Tenders Portal with an EU Login and a PIC number; two-stage (first a short proposal, then a full proposal on invitation); deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Materials
Not eligible
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Travel costs
Other costs
Actual costs in accordance with General Annex G and the Horizon Europe Model Grant Agreement; indirect costs at a flat rate of 25%. Funding rate 100%.
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 6

Subtitle
Subtitle: ChangedShow
Before

AI voor voorspellende biomarkers bij chronische niet-overdraagbare ziekten.

Now

AI for predictive biomarkers in chronic non-communicable diseases.

Description
Description: ChangedShow
Before

Projecten ontwikkelen en valideren met AI-methoden nieuwe voorspellende biomarkers voor het verloop van chronische niet-overdraagbare ziekten en de respons op behandeling. Klinische onderzoekers en ontwikkelaars krijgen zo betere instrumenten voor gepersonaliseerde zorg. Aanvragen verloopt in twee fasen.

Now

Projects use AI methods to develop and validate new predictive biomarkers for the progression of chronic non-communicable diseases and the response to treatment. This gives clinical researchers and developers better tools for personalised care. Applications follow a two-stage procedure.

Short description
Short description: ChangedShow
Before

Horizon Europe-onderzoeksactie (RIA, twee fasen) voor het ontwikkelen van voorspellende biomarkers voor ziekteprogressie en behandelrespons met AI-methoden bij chronische niet-overdraagbare ziekten.

Now

Horizon Europe research action (RIA, two-stage) to develop predictive biomarkers of disease progression and treatment response using AI methods for chronic non-communicable diseases.

Cycle
Cycle: ChangedShow
Before

Uitslag van de eerste fase rond 3 maanden na de deadline van de eerste fase en van de tweede fase rond 5 maanden na de deadline van de tweede fase; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline van de tweede fase (General Annex F).

Now

First-stage results around 3 months after the first-stage deadline and second-stage results around 5 months after the second-stage deadline; grant agreement signature around 8 months after the second-stage deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 6 projecten.

Now

Indicative topic budget, expected to fund 6 projects.

Note on the maximum
Note on the maximum: ChangedShow
Before

Geen bindend maximum; de Commissie acht € 6 mln tot € 8 mln EU-bijdrage per project passend.

Now

No binding maximum; the Commission considers an EU contribution of €6 million to €8 million per project appropriate.

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared under two different EU actions (General Annex G).

Search engine title
AI-biomarkers voor chronische ziekten (Horizon HLTH) becomes AI biomarkers for chronic diseases (Horizon HLTH)
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe-onderzoeksactie in twee fasen (circa € 6-8 mln per project) voor AI-gebaseerde voorspellende biomarkers.

Now

Two-stage Horizon Europe research action (approx. €6-8 million per project) for AI-based predictive biomarkers.

Keywords
chronische ziekten, Cluster 1 Health, Horizon Europe, HORIZON-HLTH-2027-02-TOOL-01-two-stage, kunstmatige intelligentie, voorspellende biomarkers becomes artificial intelligence, chronic diseases, Cluster 1 Health, Horizon Europe, HORIZON-HLTH-2027-02-TOOL-01-two-stage, predictive biomarkers
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Eerste fase: deel B van het korte voorstel, technische beschrijving (pdf, maximaal 10 pagina's); Tweede fase, op uitnodiging: deel B van het volledige voorstel, technische beschrijving (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat becomes Application form Part A: administrative details of the participants and summary budget (completed online); First stage: Part B of the short proposal, technical description (PDF, maximum 10 pages); Second stage, on invitation: Part B of the full proposal, technical description (PDF, maximum 40 pages); Annex with information on clinical studies (HE template), if the proposal includes clinical studies
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; two-stage (eerst een kort voorstel, daarna een volledig voorstel op uitnodiging); deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Apply via the Funding & Tenders Portal with an EU Login and a PIC number; two-stage (first a short proposal, then a full proposal on invitation); deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Other costs: Werkelijke kosten volgens General Annex G en de Horizon Europe-modelovereenkomst; indirecte kosten forfaitair 25%. Financieringspercentage 100%.

Now

Other costs: Actual costs in accordance with General Annex G and the Horizon Europe Model Grant Agreement; indirect costs at a flat rate of 25%. Funding rate 100%.

Why this scheme
Why this scheme: ChangedShow
Before

Gepersonaliseerde behandeling van chronische ziekten mogelijk maken.

Now

Enable personalised treatment of chronic diseases.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen, en ook organisaties uit de Verenigde Staten kunnen financiering krijgen. In China gevestigde organisaties en risicoleveranciers van mobiele netwerkapparatuur zijn uitgesloten.

What for: Een onderzoeks- en innovatieactie die met bestaande AI-methoden voorspellende biomarkers ontwikkelt en klinisch valideert voor het verloop en de behandelrespons van chronische niet-overdraagbare ziekten (zonder kanker). Het doel is gepersonaliseerde behandeling van chronische ziekten mogelijk te maken.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 6 tot 8 miljoen per project passend. Het indicatieve budget voor het topic is € 44,2 miljoen, naar verwachting voor 6 projecten.

What you need to do: Dien vanaf 29 oktober 2026 via het Funding & Tenders Portal eerst uiterlijk 17 februari 2027 een kort voorstel in; na uitnodiging volgt uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) het volledige voorstel met deel A en deel B. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt rond 3 maanden na de eerste en rond 5 maanden na de tweede deadline.

Now

Who: A consortium of at least three independent organisations from three different countries, at least one of which is from an EU Member State and the others from Member States or Associated Countries; companies of any size, research organisations, public authorities, foundations and associations may participate, and organisations from the United States may also receive funding. Entities established in China and high-risk suppliers of mobile network equipment are excluded.

What for: A research and innovation action that uses existing AI methods to develop and clinically validate predictive biomarkers for the progression of and treatment response in chronic non-communicable diseases (excluding cancer). The aim is to enable personalised treatment of chronic diseases.

What you get: A grant covering 100% of eligible costs; the Commission considers an EU contribution of €6-8 million per project appropriate. The indicative budget for the topic is €44.2 million, expected to fund 6 projects.

What you need to do: From 29 October 2026, first submit a short proposal via the Funding & Tenders Portal by 17 February 2027 at the latest; if invited, submit the full proposal with Part A and Part B by 16 September 2027 (17:00 Brussels time) at the latest. Independent experts evaluate and rank the proposals; results follow around 3 months after the first and around 5 months after the second deadline.

Goals
Goals: 4 removed, 4 newShow
Removed

Nieuwe voorspellende biomarkers Klinische onderzoekers en ontwikkelaars hebben toegang tot nieuwe voorspellende biomarkers om ziekteverloop en behandelrespons bij chronische niet-overdraagbare ziekten nauwkeuriger te beoordelen.

Gevalideerde biomarkers in de zorg Clinici en zorgprofessionals gebruiken klinisch gevalideerde voorspellende biomarkers voor effectiever klinisch onderzoek en gepersonaliseerde geneeskunde met betere gezondheidsuitkomsten.

Betrouwbare AI-hulpmiddelen Belanghebbenden hebben toegang tot betrouwbare AI-hulpmiddelen voor de ontwikkeling van multimodale voorspellende biomarkers die nauwkeuriger en klinisch waardevoller zijn dan de gangbare praktijk.

Betere gezondheidsuitkomsten Burgers profiteren van betere gezondheidsuitkomsten dankzij verbeterde klinische richtlijnen, biomarkergestuurd klinisch onderzoek en gepersonaliseerde zorg.

New

New predictive biomarkers Clinical researchers and developers have access to new predictive biomarkers to assess disease progression and treatment response in chronic non-communicable diseases more accurately.

Validated biomarkers in healthcare Clinicians and healthcare professionals use clinically validated predictive biomarkers for more effective clinical research and personalised medicine with better health outcomes.

Trustworthy AI tools Stakeholders have access to trustworthy AI tools for developing multimodal predictive biomarkers that are more accurate and of greater clinical value than current practice.

Better health outcomes Citizens benefit from better health outcomes thanks to improved clinical guidelines, biomarker-driven clinical research and personalised care.

Show 5 earlier versions

29 October 2026scheme · version 5

De call is op 29 oktober 2026 geopend. Voorstellen voor de eerste fase kunnen tot en met 17 februari 2027 worden ingediend; de tweede fase sluit op 16 september 2027.

Status
Opening soon becomes Open

19 October 2026scheme · version 4

Conditions
Conditions: 3 removed, 7 newShow
Removed

Consortium van minimaal 3 partijen Drie onafhankelijke juridische entiteiten uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minimaal één uit een lidstaat (General Annex B).

Entiteiten uit de Verenigde Staten subsidiabel Juridische entiteiten gevestigd in de Verenigde Staten kunnen EU-financiering ontvangen, vanwege de openstelling van NIH-programma's voor Europese onderzoekers.

Aanvraag in twee fasen Eerst een kort voorstel (fase 1); alleen geselecteerde aanvragers dienen een volledig voorstel in (fase 2).

New

To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions … – the Overseas Countries and Territories (OCTs) linked to the Member States … – countries associated to Horizon Europe … – the following low- and middle-income countries

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

Legal entities established in China are not eligible to participate in both Research and Innovation Actions (RIAs) and Innovation Actions (IAs) falling under this destination.

In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.

If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).

Entities that are assessed as high-risk suppliers of mobile network communication equipment (and any entities they own or control) are not eligible to participate as beneficiaries, affiliated entities and associated partners.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende landen, waarvan minstens één uit een EU-lidstaat en de andere uit lidstaten of geassocieerde landen; bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen, en ook organisaties uit de Verenigde Staten kunnen financiering krijgen. In China gevestigde organisaties en risicoleveranciers van mobiele netwerkapparatuur zijn uitgesloten.

What for: Een onderzoeks- en innovatieactie die met bestaande AI-methoden voorspellende biomarkers ontwikkelt en klinisch valideert voor het verloop en de behandelrespons van chronische niet-overdraagbare ziekten (zonder kanker). Het doel is gepersonaliseerde behandeling van chronische ziekten mogelijk te maken.

What you get: Een subsidie van 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 6 tot 8 miljoen per project passend. Het indicatieve budget voor het topic is € 44,2 miljoen, naar verwachting voor 6 projecten.

What you need to do: Dien vanaf 29 oktober 2026 via het Funding & Tenders Portal eerst uiterlijk 17 februari 2027 een kort voorstel in; na uitnodiging volgt uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) het volledige voorstel met deel A en deel B. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt rond 3 maanden na de eerste en rond 5 maanden na de tweede deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

The traditional ‘one biomarker’ paradigm is insufficient for addressing the unmet clinical needs of chronic, progressive and multifactorial diseases, due to the complexity of the clinical phenotypes characterised by broad inter-and intra-patient heterogeneity. The established biomarkers have limitations in their use as prognostic and predictive indicators, for the assessment of the disease progression and the choices of the optimal therapeutic interventions tailored to the patients’ characteristics. The proposals should allocate a sufficient budget for networking and joint activities, without the prerequisite to detail such activities at the proposal stage.

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de eerste fase rond 3 maanden na de deadline van de eerste fase en van de tweede fase rond 5 maanden na de deadline van de tweede fase; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline van de tweede fase (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: chronische ziekten, Cluster 1 Health, Horizon Europe, HORIZON-HLTH-2027-02-TOOL-01-two-stage, kunstmatige intelligentie, voorspellende biomarkers
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Eerste fase: deel B van het korte voorstel, technische beschrijving (pdf, maximaal 10 pagina's); Tweede fase, op uitnodiging: deel B van het volledige voorstel, technische beschrijving (pdf, maximaal 40 pagina's); Bijlage met informatie over klinische studies (HE-sjabloon), als het voorstel klinische studies omvat
Goals
Goals: 4 newShow
New

Nieuwe voorspellende biomarkers Klinische onderzoekers en ontwikkelaars hebben toegang tot nieuwe voorspellende biomarkers om ziekteverloop en behandelrespons bij chronische niet-overdraagbare ziekten nauwkeuriger te beoordelen.

Gevalideerde biomarkers in de zorg Clinici en zorgprofessionals gebruiken klinisch gevalideerde voorspellende biomarkers voor effectiever klinisch onderzoek en gepersonaliseerde geneeskunde met betere gezondheidsuitkomsten.

Betrouwbare AI-hulpmiddelen Belanghebbenden hebben toegang tot betrouwbare AI-hulpmiddelen voor de ontwikkeling van multimodale voorspellende biomarkers die nauwkeuriger en klinisch waardevoller zijn dan de gangbare praktijk.

Betere gezondheidsuitkomsten Burgers profiteren van betere gezondheidsuitkomsten dankzij verbeterde klinische richtlijnen, biomarkergestuurd klinisch onderzoek en gepersonaliseerde zorg.

7 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
17 November 2026 by the Twin editors
Start your application

Start your HORIZON-HLTH-2027-02-TOOL-01-two-stage application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.